Subsequently, GIP was shown to improve insulin sensitivity and reduce food intake, actions supporting the development of GIP-based multiagonists for the treatment of people with T2D and obesity (2, 4). This evidence concerns the gene INS and obesity due to melanocortin 4 receptor deficiency.